BONDLIDO Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Bondlido, and when can generic versions of Bondlido launch?
Bondlido is a drug marketed by Medrx Usa and is included in one NDA.
The generic ingredient in BONDLIDO is lidocaine. There are twenty-nine drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the lidocaine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Bondlido
A generic version of BONDLIDO was approved as lidocaine by ACTAVIS LABS UT INC on August 23rd, 2012.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BONDLIDO?
- What are the global sales for BONDLIDO?
- What is Average Wholesale Price for BONDLIDO?
Summary for BONDLIDO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in BONDLIDO? | BONDLIDO excipients list |
| DailyMed Link: | BONDLIDO at DailyMed |
Pharmacology for BONDLIDO
| Drug Class | Amide Local Anesthetic Antiarrhythmic |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for BONDLIDO
BONDLIDO is protected by zero US patents and one FDA Regulatory Exclusivity.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medrx Usa | BONDLIDO | lidocaine | SYSTEM;TOPICAL | 215029-001 | Sep 24, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
